azelaoyl paf

Azelaoyl PAF is a potent PPARγ agonist that competitively binds thiazolidinediones with potency comparable to rosiglitazone. In atherosclerosis studies, Azelaoyl PAF promotes the uptake of oxidized low-density lipoprotein (oxLDL) by macrophages by upregulating CD36 expression. In fibroblasts from Friedreich's ataxia (FRDA) patients, Azelaoyl PAF significantly increased mRNA and protein levels of ferritin.

Oxidized low-density lipoprotein (oxLDL) encompasses low molecular weight entities that facilitate monocyte differentiation and activate polymorphonuclear leukocytes. A substance, recently isolated and purified from oxLDL and identified as azelaoyl PC, exemplifies this. Similarly, Butanoyl PAF, a compound closely related to azelaoyl PC, maintains over 10% of the agonist potency of platelet-activating factor (PAF). Notably, Butanoyl PAF's concentration in oxLDL surpasses that of enzymatically generated PAF by more than 100-fold, making it a significant signalling molecule within oxLDL.